Loading data for ARVN — first visit, this takes a few seconds.
Arvinas, Inc. (ARVN)
NasdaqGS: ARVN
· Real-Time Price · USD
8.82
-0.26 (-2.86%)
At close: Sep 09, 2026, 1:35 PM
The price, the headline numbers and the latest news, in one place.
Arvinas, Inc. (ARVN) Stock Price, Analysis & Data
No data available
| Bid | 6.45 |
| Market Cap | 585M |
| Revenue (ttm) | 317M |
| Net Income (ttm) | 9.3M |
| 1.76 | |
| 0.26 | |
| 34.88 | |
| -2.95 | |
| P/B (ttm) | 1.05 |
| P/S (ttm) | 1.87 |
| Earnings Date | Nov 4, 2026 |
| Ask | 11.34 |
| Volume | 447,376 |
| Avg. Volume (20D) | 758,991 |
| Open | 9.05 |
| Previous Close | 9.08 |
| Day's Range | 8.79 - 9.10 |
| 52-Week Range | 6.97 - 14.51 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102,...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2018
Employees 246
Stock Exchange NasdaqGS
Ticker Symbol ARVN
Website https://www.arvinas.com
Financial Performance
In 2025, Arvinas's revenue was 262.6M, a decrease of -0.3% compared to the previous year's 263.4M. Earnings were -80.8M, a decrease of -59.38%.
Financial StatementsEarnings Surprise
Arvinas has released their quarterly earnings on Aug 4, 2026:
- Revenue of $249.7M misses estimates by $0, with 1014.73% YoY growth.
- EPS of 2.58 exceeds estimates by 2.86, with 407.14% YoY growth.
Arvinas, Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2